Seer, Inc. Receives Acquisition Proposal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy SEER?
Source: Newsfilter
- Acquisition Proposal Confirmation: Seer, Inc. has confirmed receipt of a non-binding acquisition proposal from the Radoff-JEC Group, offering $2.25 per share in cash plus a contingent value right, indicating market interest in the company's future potential.
- Board Review: The Seer Board will carefully review the proposal in consultation with independent financial and legal advisors to ensure actions align with the best interests of the company and its shareholders, reflecting the company's commitment to governance.
- Director Nominations: The Radoff-JEC Group has nominated three director candidates for the 2026 Annual Meeting, with the Board set to review these nominations according to company bylaws, highlighting shareholder influence on corporate governance.
- Proxy Statement Preparation: Seer plans to file a definitive proxy statement with the SEC detailing the Board's formal recommendations regarding the nominations, ensuring all shareholders have adequate information to make informed voting decisions at the Annual Meeting.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SEER?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SEER
About SEER
Seer, Inc. is a life sciences company. It is developing products that open a new gateway to the proteome. Its Proteograph product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. The Proteograph has detected over 36,000 proteins across multiple species, and its performance and capabilities have been demonstrated in over 33 peer-reviewed publications, preprints and reviews. The Proteograph Product Suite is detector-agnostic and is adaptable to other protein detection instruments. The MS component of the Proteograph workflow is either provided by the researcher’s laboratory, can be outsourced to a third-party provider, or be run through the Seer Technology Access Center (STAC), which is its in-house service program. It has launched Proteograph XT, which enhances the sample throughput of the Proteograph Product Suite and MS instrument.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Seer, Inc. Receives Acquisition Proposal
- Acquisition Proposal Confirmation: Seer, Inc. has confirmed receipt of a non-binding acquisition proposal from the Radoff-JEC Group, offering $2.25 per share in cash plus a contingent value right, indicating market interest in the company's future potential.
- Board Review: The Seer Board will carefully review the proposal in consultation with independent financial and legal advisors to ensure actions align with the best interests of the company and its shareholders, reflecting the company's commitment to governance.
- Director Nominations: The Radoff-JEC Group has nominated three director candidates for the 2026 Annual Meeting, with the Board set to review these nominations according to company bylaws, highlighting shareholder influence on corporate governance.
- Proxy Statement Preparation: Seer plans to file a definitive proxy statement with the SEC detailing the Board's formal recommendations regarding the nominations, ensuring all shareholders have adequate information to make informed voting decisions at the Annual Meeting.
See More
Activist Investors Bid to Acquire Seer, Inc. at $2.25 per Share
- Acquisition Proposal: The Radoff-JEC Group has launched a bid to acquire Seer, Inc. at $2.25 per share in cash, representing a 33% premium over the recent closing price, reflecting strong confidence in the company's future value.
- Shareholder Rights Assurance: The acquisition offer includes a Contingent Value Right (CVR) that guarantees shareholders 80% of net proceeds from any future sale or licensing of Seer's assets, enhancing investor expectations for long-term returns.
- Financial Conditions: The proposal is not subject to any financing conditions and promises a substantial non-performance fee to ensure the Board's ability to close the deal, while requiring Seer to maintain at least $215 million in net cash at closing.
- Management Critique: The Radoff-JEC Group sharply criticized the current CEO's performance in their letter, highlighting that $160 million in capital investment has yielded negligible revenue growth, warning that the projected $40 million cash burn in 2026 is unsustainable for shareholders.
See More
SEER INC: PATENT BOARD AFFIRMS SEER'S NANO AND MICRO PARTICLE PROTEIN ENRICHMENT PATENT AGAINST BRUKER SUBSIDIARIES' CHALLENGE
Patent Board Decision: The Patent Board has upheld Seer's patent related to nano and microparticle protein enrichment.
Challenge by Bruker: This decision comes in response to a challenge posed by Bruker Subsidiaries regarding the validity of Seer's patent.
See More
RADOFF-JEC GROUP URGES SEER BOARD TO INITIATE SALE PROCESS
- Announcement of Sale Process: The Radoff-Jec Group has called on the Seer Board to announce a sale process for the company.
- Strategic Move: This move is seen as a strategic step to enhance shareholder value and attract potential buyers.
See More
Seer, Inc. Reports Q4 2025 Earnings with Caution on Future Guidance
- Revenue Growth: Seer reported Q4 2025 revenue of $4.2 million, bringing full-year revenue to $16.6 million, reflecting a 17% year-over-year increase; however, uncertainties around NIH funding impacted customer spending decisions, leading to underperformance this quarter.
- Product Innovation: CEO Farokhzad highlighted advancements in the Proteograph ONE assay and SP200 automation instrument, enabling over 1,000 samples per week, nearly a tenfold increase from 112 samples per week in 2021, showcasing significant technological progress.
- Share Repurchase Program: The company announced a new $25 million share repurchase authorization, having repurchased 5.3 million shares in 2025, reducing total outstanding shares by 13%, aimed at enhancing shareholder value and boosting market confidence.
- Cautious Future Outlook: CFO Horn projected 2026 revenue between $16 million and $18 million, reflecting cautious customer spending in an uncertain funding environment, with management emphasizing the need for clear market momentum before increasing revenue projections.
See More
Seer Releases 2026 Financial Guidance
- Earnings Report: Seer's Q4 GAAP EPS of -$0.29 beats expectations by $0.03, indicating an improvement in profitability, although the company remains in a loss position.
- Revenue Growth: The Q4 revenue of $4.2M reflects a 5.0% year-over-year increase, yet it falls short of expectations by $0.4M, highlighting challenges in market demand that could impact future investor confidence.
- 2026 Financial Guidance: Seer anticipates full-year 2026 revenue to range between $16 million and $18 million, representing approximately 3% growth at the midpoint compared to 2025, indicating a cautiously optimistic outlook despite slowing growth.
- Market Reaction: While the Q4 EPS exceeded expectations, the revenue miss may lead investors to adopt a cautious stance regarding Seer's future performance, potentially affecting its stock price trajectory.
See More
Seer, Inc. Receives Acquisition Proposal
- Acquisition Proposal Confirmation: Seer, Inc. has confirmed receipt of a non-binding acquisition proposal from the Radoff-JEC Group, offering $2.25 per share in cash plus a contingent value right, indicating market interest in the company's future potential.
- Board Review: The Seer Board will carefully review the proposal in consultation with independent financial and legal advisors to ensure actions align with the best interests of the company and its shareholders, reflecting the company's commitment to governance.
- Director Nominations: The Radoff-JEC Group has nominated three director candidates for the 2026 Annual Meeting, with the Board set to review these nominations according to company bylaws, highlighting shareholder influence on corporate governance.
- Proxy Statement Preparation: Seer plans to file a definitive proxy statement with the SEC detailing the Board's formal recommendations regarding the nominations, ensuring all shareholders have adequate information to make informed voting decisions at the Annual Meeting.
See More
Activist Investors Bid to Acquire Seer, Inc. at $2.25 per Share
- Acquisition Proposal: The Radoff-JEC Group has launched a bid to acquire Seer, Inc. at $2.25 per share in cash, representing a 33% premium over the recent closing price, reflecting strong confidence in the company's future value.
- Shareholder Rights Assurance: The acquisition offer includes a Contingent Value Right (CVR) that guarantees shareholders 80% of net proceeds from any future sale or licensing of Seer's assets, enhancing investor expectations for long-term returns.
- Financial Conditions: The proposal is not subject to any financing conditions and promises a substantial non-performance fee to ensure the Board's ability to close the deal, while requiring Seer to maintain at least $215 million in net cash at closing.
- Management Critique: The Radoff-JEC Group sharply criticized the current CEO's performance in their letter, highlighting that $160 million in capital investment has yielded negligible revenue growth, warning that the projected $40 million cash burn in 2026 is unsustainable for shareholders.
See More
SEER INC: PATENT BOARD AFFIRMS SEER'S NANO AND MICRO PARTICLE PROTEIN ENRICHMENT PATENT AGAINST BRUKER SUBSIDIARIES' CHALLENGE
Patent Board Decision: The Patent Board has upheld Seer's patent related to nano and microparticle protein enrichment.
Challenge by Bruker: This decision comes in response to a challenge posed by Bruker Subsidiaries regarding the validity of Seer's patent.
See More
RADOFF-JEC GROUP URGES SEER BOARD TO INITIATE SALE PROCESS
- Announcement of Sale Process: The Radoff-Jec Group has called on the Seer Board to announce a sale process for the company.
- Strategic Move: This move is seen as a strategic step to enhance shareholder value and attract potential buyers.
See More
Seer, Inc. Reports Q4 2025 Earnings with Caution on Future Guidance
- Revenue Growth: Seer reported Q4 2025 revenue of $4.2 million, bringing full-year revenue to $16.6 million, reflecting a 17% year-over-year increase; however, uncertainties around NIH funding impacted customer spending decisions, leading to underperformance this quarter.
- Product Innovation: CEO Farokhzad highlighted advancements in the Proteograph ONE assay and SP200 automation instrument, enabling over 1,000 samples per week, nearly a tenfold increase from 112 samples per week in 2021, showcasing significant technological progress.
- Share Repurchase Program: The company announced a new $25 million share repurchase authorization, having repurchased 5.3 million shares in 2025, reducing total outstanding shares by 13%, aimed at enhancing shareholder value and boosting market confidence.
- Cautious Future Outlook: CFO Horn projected 2026 revenue between $16 million and $18 million, reflecting cautious customer spending in an uncertain funding environment, with management emphasizing the need for clear market momentum before increasing revenue projections.
See More
Seer Releases 2026 Financial Guidance
- Earnings Report: Seer's Q4 GAAP EPS of -$0.29 beats expectations by $0.03, indicating an improvement in profitability, although the company remains in a loss position.
- Revenue Growth: The Q4 revenue of $4.2M reflects a 5.0% year-over-year increase, yet it falls short of expectations by $0.4M, highlighting challenges in market demand that could impact future investor confidence.
- 2026 Financial Guidance: Seer anticipates full-year 2026 revenue to range between $16 million and $18 million, representing approximately 3% growth at the midpoint compared to 2025, indicating a cautiously optimistic outlook despite slowing growth.
- Market Reaction: While the Q4 EPS exceeded expectations, the revenue miss may lead investors to adopt a cautious stance regarding Seer's future performance, potentially affecting its stock price trajectory.
See More
